Medical Devices · Healthcare
Kevin Muir
Analyst
GM, Interventional Oncology
Equibles does not estimate personal net worth.
Get an email with a short summary when Delcath Systems, Inc. publishes a filing, an earnings call transcript or a press release.
Get DCTH alertsAbout Kevin Muir
Kevin Muir is recorded as Analyst at GM, Interventional Oncology. The proxy statement of Delcath Systems, Inc. reports total compensation of $1,015,984 for Kevin Muir in fiscal 2023, including a base salary of $316,272. Disclosed compensation is on record for 2 fiscal years. Kevin Muir has spoken on 3 earnings calls across 1 company, most recently for Delcath Systems, Inc. on November 9, 2026. Delcath Systems, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Delcath Systems, Inc. includes Gerard Michel (CEO and Board Member), John Purpura (CEO), Sandra Pennell (CFO) and 7 others.
Kevin Muir on recent calls
“As he mentioned earlier in the call with the 0.6 new patients, that is, it's been pretty broad based across our treatment centers. However, our larger centers have increased capacity and have, and have.”
“We are looking kind of strong for the number of new sites we're bringing on.”
“I would say that the majority of them will be going with the Chopin-like protocol. We hear a lot about just combination treatments in general, but Chopin specifically.”
Affiliation history
-
Delcath Systems, Inc. (DCTH)
Proxy statement
CurrentStart not stated–present
Last confirmed April 2, 2026
-
GM, Interventional Oncology
Analyst
Source not stated
Current
Company network
Leadership on record at Delcath Systems, Inc.
- Gerard Michel CEO, Board Member
- John Purpura CEO
- Sandra Pennell CFO
- Martha Rook COO
- Martha S. Rook COO
- David Hoffman General Counsel
- Christine Padula Chief Accounting Officer
- Bridget Martell Board Member
- Bridget Martell, M.A. M.D. Board Member
- Elizabeth Czerepak Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Delcath Systems, Inc. (DCTH) | General Manager, Interventional Oncology | $316,272 | $1,015,984 |
| 2022 | Delcath Systems, Inc. (DCTH) | General Manager, Interventional Oncology | — | — |